PPD Names Veteran Leader to Direct Clinical Operations at PPD-SNBL

WILMINGTON, N.C. -- Pharmaceutical Product Development, LLC (PPD) today announced it has appointed Yasumasa Kurioka as general manager of PPD-SNBL, the joint venture formed between PPD and Shin Nippon Biomedical Laboratories Ltd. (SNBL) earlier this year to expand clinical development services in Japan.

>>CarolinaTechNews is published by Innovative Public Relations, Inc., a North Carolina consultancy providing customized publicity and branding solutions to reach prospective customers and cement your brand in the marketplace.<<

“Yasu brings extensive clinical operations leadership experience, as well as significant scientific expertise to his position,” said Paul Colvin, executive vice president of clinical development at PPD and chairman and chief executive officer of PPD-SNBL. “I am confident he will implement innovative operational strategies that will enable PPD-SNBL to use its extensive resources, long-term experience and local expertise to further meet its clients’ needs in this important global market.”

Ryoichi Nagata, M.D., Ph.D., chairman and president of SNBL and president of PPD-SNBL, said Kurioka’s appointment will help the company generate additional opportunities in Japan. “As one of the largest clinical development service providers in Japan, PPD-SNBL already is uniquely positioned to help its clients seize opportunities in this thriving market. Yasu’s wealth of local knowledge and expertise from his years of experience in this market will enhance our already strong operational position.”

A biopharmaceutical industry veteran, Kurioka most recently served as the senior director, country head of clinical operations in Japan, for another global contract research organization. During the 20 years prior to that, he held a variety of clinical research, project management and operations leadership roles with Eli Lilly and Company and the former Ciba-Geigy in Japan. He holds a bachelor’s degree in biology and a master’s degree in microbiology, both from Hiroshima University in Japan.

As announced late last year, the joint venture combines SNBL’s clinical research division and PPD’s clinical development operations in Japan and provides a full range of services, including Phase I-IV clinical trial monitoring, project management, biostatistics, site intelligence and activation, data management, medical writing, pharmacovigilance, regulatory and FSP services.

With offices in Tokyo, Osaka and Kagoshima, and approximately 400 clinical development professionals, the joint venture brings together PPD’s global resources and clinical trial expertise with SNBL’s nearly 20-year history and in-depth knowledge of providing clinical development services for biopharmaceutical companies in Japan.

About PPD

PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 14,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.